Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: J Control Release. 2013 Jun 12;171(3):322–329. doi: 10.1016/j.jconrel.2013.06.001

Fig. 5.

Fig. 5

Anti-tumor activity of the PMLA-fusion nanobioconjugate in a murine syngeneic mammary tumor model. Animals bearing s.c. D2F2/E2 tumors received i.v. injections with either 10 μg of anti-HER2/neu IgG3-(IL-2) (n = 8) or the equivalent molar amount of PMLA-fusion nanobioconjugate (n = 8) on days 6 and 8. Control animals were injected with buffer (n = 10). Kaplan–Meier plot shows the survival of different treatment groups. Significant increase in animal survival is shown (*p < 0.05, Log-Rank test).